ABHD17C

Across TCGA pan-cancer cohorts, ABHD17C mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ABHD17C data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ABHD17C mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ABHD17C expression acts as an unfavorable survival marker.

LUAD, PDAC, and LSCC are the cancer types where ABHD17C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.836	0.968	.018	8	view →
PDAC	DFS	Median	IV	0.174	0.608	.003	6	view →
LSCC	OS	Quartile	III,IV	0.472	0.891	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ABHD17C–LUAD (DFS)

Open the LUAD breakdown →